About Neumora Therapeutics, Inc. Common Stock
https://www.neumoratx.comNeumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.
CEO
Daljit Singh Aurora
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 26
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Needham
Buy
Guggenheim
Buy
HC Wainwright & Co.
Buy
RBC Capital
Outperform
Mizuho
Outperform
Stifel
Hold
Grade Summary
Showing Top 6 of 8
Price Target
Institutional Ownership
SOFTBANK GROUP CORP.
Shares:6.54M
Value:$14.06M
BLACKROCK INC.
Shares:4.6M
Value:$9.9M
MIC CAPITAL MANAGEMENT UK LLP
Shares:4.46M
Value:$9.59M
Summary
Showing Top 3 of 101
About Neumora Therapeutics, Inc. Common Stock
https://www.neumoratx.comNeumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $52.7M ▼ | $-56.76M ▼ | 0% | $-0.35 ▼ | $-55.98M ▼ |
| Q2-2025 | $0 | $54.04M ▼ | $-52.73M ▲ | 0% | $-0.33 ▲ | $-54.02M ▲ |
| Q1-2025 | $0 | $70.94M ▲ | $-67.99M ▼ | 0% | $-0.42 ▼ | $-70.78M ▼ |
| Q4-2024 | $0 | $62.92M ▼ | $-58.82M ▲ | 0% | $-0.37 ▲ | $-62.77M ▲ |
| Q3-2024 | $0 | $76.65M | $-72.55M | 0% | $-0.45 | $-76.49M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $171.53M ▼ | $177.83M ▼ | $45.67M ▲ | $132.16M ▼ |
| Q2-2025 | $217.59M ▼ | $223.82M ▼ | $40.95M ▲ | $182.88M ▼ |
| Q1-2025 | $249.35M ▼ | $256.75M ▼ | $28.38M ▼ | $228.36M ▼ |
| Q4-2024 | $307.58M ▼ | $316.97M ▼ | $29.91M ▼ | $287.06M ▼ |
| Q3-2024 | $341.31M | $352.54M | $31.8M | $320.74M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-56.76M ▼ | $-46.63M ▲ | $51.32M ▲ | $-136K ▼ | $4.55M ▲ | $-46.65M ▲ |
| Q2-2025 | $-52.73M ▲ | $-52.4M ▲ | $30.4M ▼ | $18.46M ▲ | $-3.55M ▲ | $-52.4M ▲ |
| Q1-2025 | $-67.99M ▼ | $-59.45M ▼ | $44.16M ▲ | $0 ▼ | $-15.29M ▲ | $-59.45M ▼ |
| Q4-2024 | $-58.82M ▲ | $-50.34M ▼ | $-98.8M ▼ | $15.57M ▲ | $-133.57M ▼ | $-50.34M ▼ |
| Q3-2024 | $-72.55M | $-33.48M | $156.99M | $1.53M | $125.04M | $-33.48M |
CEO
Daljit Singh Aurora
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 26
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Needham
Buy
Guggenheim
Buy
HC Wainwright & Co.
Buy
RBC Capital
Outperform
Mizuho
Outperform
Stifel
Hold
Grade Summary
Showing Top 6 of 8
Price Target
Institutional Ownership
SOFTBANK GROUP CORP.
Shares:6.54M
Value:$14.06M
BLACKROCK INC.
Shares:4.6M
Value:$9.9M
MIC CAPITAL MANAGEMENT UK LLP
Shares:4.46M
Value:$9.59M
Summary
Showing Top 3 of 101